Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonpiretigene isteparvovec - Nanoscope Therapeutics

Next Previous
Drug Profile

Sonpiretigene isteparvovec - Nanoscope Therapeutics

Alternative Names: MCO-010; MOGENRY™; vMCO 1; vMCO-010

Latest Information Update: 12 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanoscope Therapeutics
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Eye protein replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal disorders; Stargardt disease; Retinitis pigmentosa
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Retinitis pigmentosa
  • Phase II Stargardt disease
  • Preclinical Leber congenital amaurosis
  • No development reported Dry age-related macular degeneration

Most Recent Events

  • 24 Feb 2026 Nanoscope therapeutics plans a phase III STARGAZE registrational trial for Stargardt disease (Intravitreous) in 2026
  • 20 Jan 2026 Sonpiretigene isteparvovec - Nanoscope Therapeutics receives Orphan Drug status for Retinal disorders in Japan
  • 20 Jan 2026 Sonpiretigene isteparvovec - Nanoscope Therapeutics receives Sakigake designation for Retinal disorders in Japan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top